GlobeNewswire Inc | Feb 17, 2021 04:03PM EST

February 17, 2021

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

SVB Leerink 10^th Annual Global Healthcare ConferenceFebruary 26, 2021Fireside chat presentation: 1:40 p.m. ET

Cowen 41^st Annual Health Care ConferenceMarch 3-4, 2021No presentation

Barclays Global Healthcare ConferenceMarch 11, 2021Fireside chat presentation: 10:20 a.m. ET

Live audio webcasts of the presentations will be available on the Investors section of Nkartas website, www.nkartatx.com. Replays of the webcasts will be archived on the website for approximately four weeks.

About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the companys website at www.nkartatx.com.

Nkarta Media/Investor Contact:Greg MannNkarta, Inc.gmann@nkartatx.com